- Home
- RNXT vs IMA Comparison
RNXT vs IMA Comparison
Compare RNXT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | IMA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4M | 66.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RNXT | IMA |
|---|---|---|
| Price | $1.52 | $4.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $7.13 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.1M | 12.3K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,000.00 | $800,000.00 |
| Revenue This Year | $244.84 | N/A |
| Revenue Next Year | $195.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $3.94 |
| 52 Week High | $2.59 | $9.10 |
Technical Indicators
Market Signals| Indicator | RNXT | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 30.75 |
| Support Level | $1.55 | $3.94 |
| Resistance Level | $1.80 | $6.13 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 22.86 | 1.22 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.